Alpha Bio

With an AstraZeneca cancer drug in one hand, $37M in the other, Shanghai’s Alpha Bio zooms into a PhII study
Endpoints
Wed, 06/20/18 - 09:47 am
China
Alpha Bio
AstraZeneca